{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:26:12Z","timestamp":1747369572030},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s12094-017-1616-3","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T12:26:28Z","timestamp":1485865588000},"page":"915-920","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy"],"prefix":"10.1007","volume":"19","author":[{"given":"L.","family":"de la Cueva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lloro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Sangr\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"L\u00f3pez V\u00e9lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Sarria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ab\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,31]]},"reference":[{"key":"1616_CR1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/BF02793931","volume":"25","author":"M Bangard","year":"1998","unstructured":"Bangard M, B\u00e9h\u00e9 M, Bender H, Guhlke S, Willkomm P, Risse J, et al. Technetium-99m-octreotide for the detection of somatostatin receptor positive (SSTR+) tumors: preliminary results [abstract]. Eur J Nucl Med. 1998;25:837.","journal-title":"Eur J Nucl Med"},{"key":"1616_CR2","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s002590050556","volume":"27","author":"M Bangard","year":"2000","unstructured":"Bangard M, Behe M, Guhlke S, Otte R, Bender H, Maecke HR, et al. Detection of somatostatin receptor-positive tumours using the new [99mTc]-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111 in-DTPA-D-Phe1-octreotide. Eur J Nucl Med. 2000;27:628\u201337.","journal-title":"Eur J Nucl Med"},{"key":"1616_CR3","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00259-006-0113-7","volume":"33","author":"A Hubalewska-Dydejczyk","year":"2006","unstructured":"Hubalewska-Dydejczyk A, Fr\u00f6ss-Baron K, Miko\u0142ajczak R, Maecke HR, Huszno B, Pach D, et al. [99mTc]-EDDA\/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3\u00a0years experience. Eur J Nucl Med Mol Imaging. 2006;33:1123\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1616_CR4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/RLU.0b013e31825b2555","volume":"37","author":"J Kunikowska","year":"2012","unstructured":"Kunikowska J, Kr\u00f3licki L, Pawlak D, Zerizer I, Miko\u0142ajczak R. Semiquantitative analysis and characterization of physiological biodistribution of (68) Ga-DOTA-TATE PET\/CT. Clin Nucl Med. 2012;37:1052\u20137.","journal-title":"Clin Nucl Med"},{"key":"1616_CR5","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1148\/rg.352140164","volume":"35","author":"MS Hofman","year":"2015","unstructured":"Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls and pitfalls in interpretation. RadioGraphics. 2015;35:500\u201316.","journal-title":"RadioGraphics"},{"key":"1616_CR6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MNM.0000000000000106","volume":"35","author":"P Mapelli","year":"2014","unstructured":"Mapelli P, Tam HH, Sharma R, Aboagye EO, Al-Nahhas A. Frequency and significance of physiological versus pathological uptake of 68Ga-DOTATATE in the pancreas: validation with morphological imaging. Nucl Med Commun. 2014;35:613\u20139.","journal-title":"Nucl Med Commun"},{"key":"1616_CR7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/RLU.0b013e3182393404","volume":"37","author":"Y Krausz","year":"2012","unstructured":"Krausz Y, Rubinstein R, Appelbaum L, Mishani E, Orevi M, Fraenkel M, et al. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin Nucl Med. 2012;37:57\u201362.","journal-title":"Clin Nucl Med"},{"key":"1616_CR8","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2967\/jnumed.111.088328","volume":"52","author":"P Castellucci","year":"2011","unstructured":"Castellucci P, Ucha JP, Fuccio C, Rubello D, Ambrosini V, Montini GC, et al. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET\/CT. J Nucl Med. 2011;52:886\u201390.","journal-title":"J Nucl Med"},{"key":"1616_CR9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/RLU.0b013e3182485110","volume":"37","author":"H Jacobsson","year":"2012","unstructured":"Jacobsson H, Larsson P, Jonsson C, Jussing E, Gryb\u00e4ck P. Normal uptake of 68Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET. Clin Nucl Med. 2012;37:362\u20135.","journal-title":"Clin Nucl Med"},{"key":"1616_CR10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/MNM.0b013e32834e0974","volume":"33","author":"S Chondrogiannis","year":"2012","unstructured":"Chondrogiannis S, Grassetto G, Marzola MC, Rampin L, Massaro A, Bellan E, et al. 18F-DOPA PET\/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours. Nucl Med Commun. 2012;33:179\u201384.","journal-title":"Nucl Med Commun"},{"key":"1616_CR11","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","volume":"37","author":"I Virgolini","year":"2010","unstructured":"Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET\/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1616_CR12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11547-015-0593-2","volume":"121","author":"LY Yamaga","year":"2016","unstructured":"Yamaga LY, Neto GC, da Cunha ML, Osawa A, Oliveira JC, Fonseca RQ, et al. [99mTc]-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT\/CT. Radiol Med. 2016;121:225\u20138.","journal-title":"Radiol Med."},{"key":"1616_CR13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4274\/Mirt.68552","volume":"22","author":"E Ko\u00e7yi\u011fit Deveci","year":"2013","unstructured":"Ko\u00e7yi\u011fit Deveci E, Ocak M, Bozkurt MF, T\u00fcrker S, Kabasakal L, U\u011fur O. The diagnostic efficiency of 99mTc-EDDA\/HYNIC-Octreotate SPECT-CT in comparison with 111 in-pentetrotide in the detection of neuroendocrine tumours. Mol Imaging Radionucl Ther. 2013;22:76\u201384.","journal-title":"Mol Imaging Radionucl Ther"},{"key":"1616_CR14","first-page":"708","volume":"44","author":"M Gabriel","year":"2003","unstructured":"Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, et al. An intrapatient comparison of 99mTc-EDDA\/HYNIC-TOC with 111 in-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44:708\u201316.","journal-title":"J Nucl Med"},{"key":"1616_CR15","first-page":"114","volume":"41","author":"C Decristoforo","year":"2000","unstructured":"Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: monodose evaluation and comparison with 111 in-octreotide. J Nucl Med. 2000;41:114\u20139.","journal-title":"J Nucl Med"},{"key":"1616_CR16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2013.11.001","volume":"442","author":"T Sako","year":"2013","unstructured":"Sako T, Hasegawa K, Nishimura M, Kanayama Y, Wada Y, Hayashinaka E, et al. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement. Biochem Biophys Res Commun. 2013;442:79\u201384.","journal-title":"Biochem Biophys Res Commun"},{"key":"1616_CR17","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","volume":"10","author":"EP Krenning","year":"1999","unstructured":"Krenning EP, de Jong M, Kooij PPM, Breeman WAP, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10:S23\u20139.","journal-title":"Ann Oncol"},{"key":"1616_CR18","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.gastro.2010.07.002","volume":"139","author":"KE Oberg","year":"2010","unstructured":"Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Oberg KE1, Reubi JC, Kwekkeboom DJ, Krenning EP. Gastroenterology. 2010;139:742\u201353.","journal-title":"Gastroenterology"},{"key":"1616_CR19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"YC Patel","year":"1999","unstructured":"Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157\u201398.","journal-title":"Front Neuroendocrinol"},{"key":"1616_CR20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1055\/s-0032-1314859","volume":"120","author":"N Unger","year":"2012","unstructured":"Unger N, Ueberberg B, Schulz S, Saeger W, Mann K, Petersenn S. Differential expression of somatostatin receptor subtype 1-5 proteins in numerous normal human tissues. Exp Clin Endocrinol Diabetes. 2012;120:482\u20139.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1616_CR21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi JC, Sch\u00e4r JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes of radiotracers selected for scintigraphic and radiotherapeutic somatostatin SST1-SST5 use. Eur J Nucl Med. 2000;27:273\u201382.","journal-title":"Eur J Nucl Med"},{"key":"1616_CR22","doi-asserted-by":"crossref","first-page":"C61","DOI":"10.5603\/NMR.2012.0011","volume":"15","author":"J Kunikowska","year":"2012","unstructured":"Kunikowska J, Kr\u00f3licki L. PET receptor imaging in clinical oncology. Nucl Med Rev. 2012;15:C61\u20133.","journal-title":"Nucl Med Rev"},{"key":"1616_CR23","unstructured":"Gandomkar M, Najafi R, Rabbani M. 99mTc-EDDA-Tricine-HYNIC-TOC versus 99mTc-EDDA-Tricine-HYNIC-TATE: synthesis and monodose result of two new radiopharmaceuticals for somatostatin receptor scintigraphy. International Atomic Energy Agency, Division of Physical and Chemical Sciences and Division of Human Health, Vienna (Austria); 2005. p. 348, 180; ISTR-2005: International symposium on trends in radiopharmaceuticals; Vienna (Austria); 14\u201318 Nov 2005; IAEA-CN-130; IAEA-CN-130\/096P."},{"key":"1616_CR24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12020-012-9631-1","volume":"42","author":"G Treglia","year":"2012","unstructured":"Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET\/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42:80\u20137.","journal-title":"Endocrine"},{"key":"1616_CR25","unstructured":"O\u2019Sullivan AW, Heaton N, Rela M. Cancer of the uncinate process of the pancreas: surgical anatomy and clinicopathological features. Hepatobiliary Pancreat Dis Int. 2009; 8(6):569\u201374."},{"key":"1616_CR26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2337\/diabetes.28.1.11","volume":"28","author":"DJ Gersell","year":"1979","unstructured":"Gersell DJ, Gingerich RL, Greider MH. Regional distribution and concentration of pancreatic polypeptide in the human and canine pancreas. Diabetes. 1979;28:11\u20135.","journal-title":"Diabetes"},{"key":"1616_CR27","first-page":"126","volume":"8","author":"GM Portela-Gomes","year":"2000","unstructured":"Portela-Gomes GM, Stridsberg M, Grimelius L, Oberg K, Janson ET. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol. 2000;8:126\u201332.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"1616_CR28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00259-012-2309-3","volume":"40","author":"A Kroiss","year":"2013","unstructured":"Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological and pathological processes in PET\/CT uptake. Eur J Nucl Med Mol Imaging. 2013;40:514\u201323.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1616_CR29","first-page":"61","volume":"54","author":"V Prasad","year":"2010","unstructured":"Prasad V, Baum PR. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumour lesions. Q J Nucl Med Mol Imaging. 2010;54:61\u20137.","journal-title":"Q J Nucl Med Mol Imaging."},{"key":"1616_CR30","doi-asserted-by":"publisher","first-page":"926295","DOI":"10.1155\/2013\/926295","volume":"2013","author":"F Barbieri","year":"2013","unstructured":"Barbieri F, Bajetto A, Pattarozzi A, Gatti M, W\u00fcrth R, Thellung S, et al. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept. 2013;2013:926295. doi:\n                        10.1155\/2013\/926295\n                        \n                    .","journal-title":"Int J Pept."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-017-1616-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1616-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1616-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T11:13:54Z","timestamp":1497352434000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-017-1616-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,31]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["1616"],"URL":"https:\/\/doi.org\/10.1007\/s12094-017-1616-3","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,31]]}}}